China International Capital Valuation
Is 3908 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 3908 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 3908 (HK$14.08) is trading below our estimate of fair value (HK$14.61)
Significantly Below Fair Value: 3908 is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 3908?
Key metric: As 3908 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 3908's PE Ratio? | |
|---|---|
| PE Ratio | 16.9x |
| Earnings | CN¥3.75b |
| Market Cap | CN¥131.32b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | 0.7x |
Price to Earnings Ratio vs Peers
How does 3908's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 26.6x | ||
6881 China Galaxy Securities | 10.4x | 9.8% | HK$152.1b |
6066 CSC Financial | 16.5x | 38.6% | HK$211.9b |
1456 Guolian Securities | 33.8x | 44.8% | HK$33.6b |
1375 Central China Securities | 45.8x | n/a | HK$19.2b |
3908 China International Capital | 16.9x | 25.8% | HK$141.1b |
Price-To-Earnings vs Peers: 3908 is good value based on its Price-To-Earnings Ratio (16.9x) compared to the peer average (26.6x).
Price to Earnings Ratio vs Industry
How does 3908's PE Ratio compare vs other companies in the HK Capital Markets Industry?
Price-To-Earnings vs Industry: 3908 is good value based on its Price-To-Earnings Ratio (16.9x) compared to the Hong Kong Capital Markets industry average (19.1x).
Price to Earnings Ratio vs Fair Ratio
What is 3908's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 16.9x |
| Fair PE Ratio | 15.9x |
Price-To-Earnings vs Fair Ratio: 3908 is expensive based on its Price-To-Earnings Ratio (16.9x) compared to the estimated Fair Price-To-Earnings Ratio (15.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | HK$14.08 | HK$16.68 +18.5% | 27.9% | HK$24.42 | HK$10.51 | n/a | 12 |
| Nov ’25 | HK$14.20 | HK$17.01 +19.8% | 27.6% | HK$24.78 | HK$10.67 | n/a | 12 |
| Oct ’25 | HK$13.90 | HK$12.41 -10.7% | 17.0% | HK$16.03 | HK$9.44 | n/a | 12 |
| Sep ’25 | HK$8.37 | HK$12.59 +50.4% | 20.1% | HK$16.77 | HK$9.36 | n/a | 12 |
| Aug ’25 | HK$8.65 | HK$12.95 +49.7% | 17.1% | HK$16.37 | HK$9.50 | n/a | 12 |
| Jul ’25 | HK$8.69 | HK$13.85 +59.4% | 24.2% | HK$22.97 | HK$10.31 | n/a | 13 |
| Jun ’25 | HK$9.30 | HK$13.85 +48.9% | 24.2% | HK$22.97 | HK$10.31 | n/a | 13 |
| May ’25 | HK$9.52 | HK$13.91 +46.1% | 24.5% | HK$22.97 | HK$10.09 | n/a | 13 |
| Apr ’25 | HK$9.28 | HK$16.35 +76.1% | 25.4% | HK$23.74 | HK$10.09 | n/a | 13 |
| Mar ’25 | HK$10.00 | HK$16.94 +69.4% | 23.4% | HK$23.85 | HK$11.23 | n/a | 13 |
| Feb ’25 | HK$9.31 | HK$17.52 +88.2% | 21.3% | HK$23.88 | HK$11.24 | n/a | 13 |
| Jan ’25 | HK$11.46 | HK$19.31 +68.5% | 15.2% | HK$24.00 | HK$12.41 | n/a | 14 |
| Dec ’24 | HK$12.20 | HK$19.50 +59.8% | 14.5% | HK$24.28 | HK$13.82 | n/a | 14 |
| Nov ’24 | HK$12.36 | HK$19.19 +55.3% | 15.7% | HK$23.71 | HK$13.50 | HK$14.20 | 14 |
| Oct ’24 | HK$14.36 | HK$19.87 +38.4% | 14.8% | HK$24.06 | HK$13.94 | HK$13.90 | 14 |
| Sep ’24 | HK$15.08 | HK$20.53 +36.1% | 13.0% | HK$24.98 | HK$15.10 | HK$8.37 | 14 |
| Aug ’24 | HK$16.60 | HK$20.72 +24.8% | 11.0% | HK$24.22 | HK$16.31 | HK$8.65 | 14 |
| Jul ’24 | HK$13.74 | HK$20.95 +52.5% | 11.1% | HK$24.50 | HK$16.50 | HK$8.69 | 14 |
| Jun ’24 | HK$14.24 | HK$21.19 +48.8% | 10.5% | HK$24.71 | HK$17.98 | HK$9.30 | 14 |
| May ’24 | HK$16.42 | HK$21.48 +30.8% | 10.3% | HK$25.30 | HK$18.41 | HK$9.52 | 14 |
| Apr ’24 | HK$15.74 | HK$20.61 +31.0% | 11.7% | HK$24.80 | HK$15.45 | HK$9.28 | 15 |
| Mar ’24 | HK$17.32 | HK$20.32 +17.3% | 14.9% | HK$28.07 | HK$15.29 | HK$10.00 | 15 |
| Feb ’24 | HK$18.20 | HK$20.56 +12.9% | 15.4% | HK$28.66 | HK$15.61 | HK$9.31 | 15 |
| Jan ’24 | HK$14.90 | HK$19.86 +33.3% | 19.1% | HK$27.60 | HK$13.60 | HK$11.46 | 17 |
| Dec ’23 | HK$14.70 | HK$19.58 +33.2% | 19.5% | HK$26.89 | HK$13.25 | HK$12.20 | 17 |
| Nov ’23 | HK$11.36 | HK$19.92 +75.4% | 17.6% | HK$26.50 | HK$13.06 | HK$12.36 | 17 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
CSSC (Hong Kong) Shipping
HK$10.0b
Operates as a shipyard-affiliated leasing company in People Republic of China, Asia, the United States, and Europe.
3877
HK$1.62
7D
1.9%
1Y
17.4%
Genertec Universal Medical Group
HK$9.0b
Offers financing and advisory services in the People’s Republic of China.
2666
HK$4.78
7D
-1.4%
1Y
14.1%
CSC Financial
HK$211.9b
Provides investment banking services in Mainland China and internationally.
6066
HK$10.66
7D
0%
1Y
37.7%